3HANSEN L B. Method for acylating peptides and novel acylating agents: WO,2000/55119 [ P]. 2000 - 09 - 21. 被引量：1
4STURIS J,GOTFREDSEN C F,ROMER J,et al. GLP-1 derivative liraglutide in rats with b-cell deficiencies:influence of metabolic state on b-cell mass dynamics[ J]. Br J Pharmacol, 2003,140( 1 ) :123 - 132. 被引量：1
5MEIER J J, NAUCK M A. Glucagon-like peptide 1 ( GLP-1 ) in biology and pathology[ J]. Diabetes Metab Res Rev ,2005, 21(2) :91 -117. 被引量：1
6SEINO Y, RASMUSSEN M F, ZDRAVKOVIC M, et al. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind randomized,controlled trial in Japanese patients with type 2 diabetes [ J ]. Diabetes Res Clin Pract, 2008, 81 ( 2 ) : 161 -168. 被引量：1
7MADSBAD S, SCHMITZ O, RANSTAM J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide ( NN2211 ) : a 12- week,double-blind, randomized, controlled trial [ J ]. Diabetes Care,2004,27(6) :1335 - 1342. 被引量：1
6Jain D, Panda A K, Majumdar D K. Eudragit S100 entrapped insulin microspheres for oral delivery[J]. AAPS Pharm Sci Tech,2005,6(1):100. 被引量：1
7Chalasani K B, Russell-Jones G J, Jain A K, et al. Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles[J]. J Control Release,2007,122(2):141. 被引量：1
